BridgeBio Pharma, Inc. financial metrics

Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q1 2026.

Public ticker
BBIO on Nasdaq
Latest financial report
07 May 2026
Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Palo Alto, CA
SEC filing record 1 source field available
Fiscal year end
31 December

Shareable Research Card

BBIO - BridgeBio Pharma, Inc. Financial Facts

BBIO - BridgeBio Pharma, Inc. has a source-backed company facts page for reviewing reported financial metrics, periods, and linked metric histories.

Start with the latest metric summary, then open metric histories or cross-company rankings to compare the same SEC-backed facts.

Context
Latest metrics period: Q1 2026
Latest reported value
Return On Assets -28%

Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.

Open stable link Open latest 10-Q/10-K hub Which companies report the highest revenue?

Return Loop

Why revisit this company facts page

Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.

Latest source-backed update
Latest metrics period Q1 2026
Why come back
Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
  • Current latest metrics period: Q1 2026.
  • Most recent SEC facts end date on this page: 30 Apr 2026.
  • Save this filer to return when the next filing-backed metric period changes the picture.

Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.

Create account to save this filer Open latest 10-Q/10-K hub

Latest update

Latest update for BBIO - BridgeBio Pharma, Inc.

New fact period available

Latest financial period: Q1 2026. Reopen this facts page to verify the newest reported period against the prior baseline.

Update date

07 May 2026

Page type

Company facts

Latest period

Q1 2026

SEC-backed company facts were refreshed from filings filed on 07 May 2026.

Open recent updates hub Open latest 10-Q/10-K hub

Benchmark Context

How Return On Assets compares

Return On Assets does not yet have enough prior-period data for a historical comparison on this page.

Compared with

Compared with BridgeBio Pharma, Inc.'s recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.

Why this is notable

Return On Assets already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.

  • Latest comparable period on this page: Q1 2026.
  • Peer context will appear when enough companies report a comparable value for this metric.
  • Open the metric history first if you want to verify the exact period-to-period change.

Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.

Open Revenues YoY history Which companies report the highest revenue?

How to read key metrics on this page

These short guides explain what the headline metrics mean, what to compare next, and where to open the live SEC-backed example for this company.

Plain-English Guide

How to read Revenue on this page

Revenue is the sales a company reports from customers before most expenses are subtracted.

Why people care

People start here to understand business scale and whether demand is growing before they ask about margins or cash flow.

How to read it

Check the latest reported period first, then compare the same quarter or year against prior periods so seasonality does not distort the story.

Compare next

Compare revenue with gross profit, operating income, and operating cash flow to see whether sales are turning into healthy economics.

Revenue can jump because of acquisitions, pricing changes, or revenue-recognition rules, and reporting periods may differ across companies.

Open a live SEC-backed example

Open Revenue guide

Save this filer page

Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.

Create free account and save this filer Already have an account? Sign in and save it

Key facts

  • BBIO - BridgeBio Pharma, Inc. financial facts are built from SEC company filings data.
  • Latest metrics period on this page: Q1 2026.
  • Headline metric: Return On Assets -28%.

Change

  • Return On Assets YoY change: .
  • Most recent SEC facts end date: 30 Apr 2026.

Research use

  • This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
  • Every metric card links to a deeper SEC-backed history page for verification.

Evidence

Based on latest 10-Q/10-K

Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.

View source filing

Latest SEC snapshot (2026-04-30) highlights Return On Assets -28.0%, Operating Margin -54.5%, and Current Ratio 1.52x.

Valuation Snapshot

SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.

DCF value materially below price Overvalued Low confidence

-142%

fair value gap

Fair value per share

$28.76

Market price

$68.45

BBIO - Local security

PEG ratio

n/a

Enterprise value

$6.48B

Equity value

$5.6B

DCF fair value scenarios

Bear

$20.32

Overvalued
Growth
1%
Discount
11%
Terminal
2%

Gap -130%

Base

$28.76

Overvalued
Growth
4%
Discount
10%
Terminal
2.5%

Gap -142%

Bull

$42.05

Overvalued
Growth
7%
Discount
9%
Terminal
3%

Gap -161%

Base growth: DCF Growth Assumption.

Key valuation metrics

EV/Revenue

21.5x

Local security market EV / SEC revenue

EV/EBITDA

n/a

Local security market EV / SEC EBITDA

Ebitda is unavailable or not positive

P/E

n/a

Local security market price / SEC EPS

Net income is unavailable or not positive

P/S

23.0x

Local security market cap / SEC revenue

P/B

n/a

Local security market cap / SEC equity

Equity is unavailable or not positive

PEG

n/a

P/E / DCF Growth Assumption

P/e or positive growth is unavailable

Core assumptions

Projection
5 years
FCF growth
4%
Discount rate
10%
Terminal growth
2.5%

SEC fact inputs

DCF base FCF
$445.12M
Trailing SEC FCF
Reported FCF
$445.12M
Net income
n/a
EBITDA
$519.66M
Cash
$879.89M
Debt
n/a
Equity
$2.28B
Shares
194,789,897

Data confidence notes

  • Dcf base free cash flow: dcf base starts from trailing sec free cash flow
  • Dcf base free cash flow: trailing free cash flow is not positive
  • Dcf confidence is low for this sec-only free cash flow estimate
  • Debt missing: equity value treats debt as 0
  • Base free cash flow is negative; dcf output is mechanically computed but high risk
  • Peg unavailable: net income is missing

Compare This Company Through SEC-backed Metrics

Use these links to compare BBIO - BridgeBio Pharma, Inc. against other SEC filers on the same metric, then verify the company history from the paired facts page.

Financial Quality Score

Transparent 0-100 scoring model based on profitability, financial health, and growth factors.

66.7/100

Balanced Confidence low

Return On Assets

-28%

Metric score 0.0/100

Financial Health

Current Ratio
1.52x
Quick Ratio
1.4x

Strengths

Current Ratio, Quick Ratio, and Revenues YoY

Watchpoints

Return On Assets and Operating Margin

Key metrics snapshot

Profitability

Metric Latest value YoY change
Return On Assets -28%
Operating Margin -54% -83%

Financial Health

Metric Latest value YoY change
Current Ratio 1.52x -67%
Quick Ratio 1.4x -69%

Growth

Metric Latest value YoY change
Revenues YoY 355%

Share Metrics

Metric Latest value YoY change
Entity Common Stock, Shares Outstanding 195,861,242 +3.2%
Common Stock, Shares, Outstanding 195,707,702 +3.1%
Common Stock, Value, Issued $204,000 +3.6%
Weighted Average Number of Shares Outstanding, Basic 194,789,897 +2.4%
Weighted Average Number of Shares Outstanding, Diluted 194,789,897 +2.4%

Supporting Metrics

These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.

Metric Latest value YoY change
Accounts Payable, Current $29,058,000 +5.6%
Accounts Receivable, after Allowance for Credit Loss, Current $205,226,000 +78%
Accumulated Other Comprehensive Income (Loss), Net of Tax $8,000
Additional Paid in Capital $2,112,454,000
Amortization of Intangible Assets $2,800,000 +17%
Assets $1,370,981,000 +56%
Assets, Current $1,241,306,000 +79%
Cash and Cash Equivalents, at Carrying Value $879,891,000 +63%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $882,018,000 +63%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $309,878,000
Common Stock, Par or Stated Value Per Share 0.001 0%
Common Stock, Shares Authorized 500,000,000 0%
Common Stock, Shares, Issued 204,386,699 +3.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $721,560,000 -8%
Contract with Customer, Liability, Current $6,115,000
Contract with Customer, Liability, Noncurrent $11,776,000
Cost of Revenue $28,262,000 +377%
Costs and Expenses $1,104,953,000 +34%
Depreciation, Depletion and Amortization $1,186,000 -7.6%
Earnings Per Share, Basic -3.74 -5.1%
Earnings Per Share, Diluted -3.74 -5.1%
Employee-related Liabilities, Current $39,338,000 +18%
Increase (Decrease) in Accounts Receivable $65,782,000 -40%
Intangible Assets, Net (Excluding Goodwill) $27,359,000 -1.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities $20,316,000 -13%
Inventory, Net $32,980,000 +734%
Lessee, Operating Lease, Liability, to be Paid $23,455,000 +112%
Lessee, Operating Lease, Liability, to be Paid, Year Four $2,857,000 +507%
Lessee, Operating Lease, Liability, to be Paid, Year One $2,180,000 -44%
Lessee, Operating Lease, Liability, to be Paid, Year Three $2,787,000 +535%
Lessee, Operating Lease, Liability, to be Paid, Year Two $3,199,000 +634%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $4,800,000 +424%
Liabilities $3,639,856,000 +44%
Liabilities and Equity $1,370,981,000 +56%
Liabilities, Current $816,372,000 +437%
Net Cash Provided by (Used in) Financing Activities $549,892,000 +812%
Net Cash Provided by (Used in) Investing Activities $42,735,000 -2579%
Net Cash Provided by (Used in) Operating Activities $197,279,000 +0.98%
Nonoperating Income (Expense) $204,455,000 -1027%
Operating Income (Loss) $524,995,000 +25%
Operating Lease, Liability $18,655,000 +84%
Operating Lease, Liability, Current $4,439,000 -15%
Operating Lease, Liability, Noncurrent $14,216,000 +189%
Operating Lease, Payments $1,852,000 +26%
Operating Lease, Right-of-Use Asset $17,226,000 +140%
Other Assets, Noncurrent $18,620,000 +12%
Other Liabilities, Noncurrent $229,000 -35%
Other Noncash Income (Expense) $306,000 -1557%
Payments to Acquire Property, Plant, and Equipment $69,000
Preferred Stock, Par or Stated Value Per Share 0.001 0%
Preferred Stock, Shares Authorized 25,000,000 0%
Preferred Stock, Shares Issued 0
Preferred Stock, Shares Outstanding 0
Property, Plant and Equipment, Net $4,941,000 -26%
Research and Development Expense $467,158,000 -2%
Retained Earnings (Accumulated Deficit) $3,985,237,000 -22%
Revenue from Contract with Customer, Excluding Assessed Tax $579,958,000 +355%
Share-based Payment Arrangement, Expense $140,855,000 +23%
Share-based Payment Arrangement, Noncash Expense $33,242,000 +28%
Stockholders' Equity Attributable to Parent $2,278,363,000 -38%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $2,267,924,000 -38%

How we score

This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.

Metric Weight V1 threshold
ROIC205% to 20%
ROE158% to 25%
ROA102% to 10%
Operating Margin55% to 25%
Current Ratio121.0x to 2.0x
Quick Ratio80.8x to 1.5x
Debt to Equity100.3x to 2.0x (lower is better)
Revenue YoY10-10% to +20%
Net Income YoY10-10% to +20%

How Calculated (standard_v1)

Metrics are computed with a market-consensus convention designed for cross-portal comparability.

  • TTM Operating Income / TTM Revenues
  • Current Assets / Current Liabilities (latest instant quarter)
  • (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
  • Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
  • TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
  • TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
  • TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
  • TTM Revenues YoY
  • TTM Net Income YoY
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .